Alembic Pharmaceuticals, 533573, APLLTD Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

18,116.24
28.56
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

19,387.18
1.19%
3.41

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

7.74
4.35
5.68

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-0.02
-7.49
7.21

PAT CAGR (%)

10 Years
5 Years
3 Years

-2.08
-12.15
19.49

P:E (Median)

8 Years
5 Years
3 Years

25.24
29.64
32.35

P:BV (Average)

8 Years
5 Years
3 Years

3.70
3.35
3.45

EV:EBITDA (Average)

8 Years
5 Years
3 Years

15.89
17.02
19.04

Earnings Forecasts:

(Updated: 01-11-2025)

Description 2024 2025 2026 2027
Adj EPS 29.68 35.03 44.11 53.11
P/E Ratio 31.06 26.32 20.90 17.36
Revenue 6672.08 7360.13 8139.14 8933.54
EBITDA 1008.23 1202.01 1432.85 1668.68
Net Income 583.42 688.24 866.63 1043.83
ROA 8.21 10.26 12.37 13.7
P/B Ratio 3.49 3.19 2.86 2.53
ROE 11.66 12.81 14.68 16.57
FCFF -547.67 663.38 562.19 739.05
FCFF Yield -2.81 3.4 2.88 3.79
Net Debt 1167.4 692.73 463.96 177.87
BVPS 264.09 288.95 322.36 363.79

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Sep 25 Sep 24 Var% Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var%
Net Sales 1,796.24 1,580.35 13.66% 1,494.17 1,475.56 1.26% 1,570.64 1,474.55 6.52% 1,406.09 1,588.39 -11.48%
Expenses 1,492.93 1,320.86 13.03% 1,280.43 1,184.13 8.13% 1,399.98 1,186.36 18.01% 1,226.26 1,251.25 -2.00%
EBITDA 303.31 259.49 16.89% 213.74 291.43 -26.66% 170.66 288.19 -40.78% 179.83 337.14 -46.66%
EBIDTM 16.89% 16.42% 14.30% 19.75% 10.87% 19.54% 12.79% 21.23%
Other Income 11.49 16.06 -28.46% 7.79 3.14 148.09% 13.21 7.22 82.96% 15.46 3.30 368.48%
Interest 22.81 18.28 24.78% 22.64 12.69 78.41% 23.71 10.13 134.06% 21.79 14.66 48.64%
Depreciation 75.64 70.12 7.87% 73.37 68.68 6.83% 68.60 69.12 -0.75% 69.69 69.08 0.88%
PBT 216.35 200.02 8.16% 125.52 213.20 -41.13% 91.56 216.16 -57.64% 103.81 256.70 -59.56%
Tax 36.99 34.24 8.03% 22.00 37.01 -40.56% 16.22 14.29 13.51% 18.00 23.46 -23.27%
PAT 179.36 165.78 8.19% 103.52 176.19 -41.25% 75.34 201.87 -62.68% 85.81 233.24 -63.21%
PATM 9.99% 10.49% 6.93% 11.94% 4.80% 13.69% 6.10% 14.68%
EPS 9.12 8.43 8.19% 5.27 8.96 -41.18% 3.83 10.27 -62.71% 4.36 11.86 -63.24%

Description Sep 25 Sep 24 Var% Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var%
Net Sales 1,910.15 1,647.98 15.91% 1,710.72 1,561.73 9.54% 1,769.64 1,516.97 16.66% 1,692.75 1,630.57 3.81%
Expenses 1,594.46 1,408.71 13.19% 1,429.38 1,324.90 7.89% 1,497.71 1,256.92 19.16% 1,432.52 1,364.21 5.01%
EBITDA 315.69 239.27 31.94% 281.34 236.83 18.79% 271.93 260.05 4.57% 260.23 266.36 -2.30%
EBIDTM 16.53% 14.52% 16.45% 15.16% 15.37% 17.14% 15.37% 16.34%
Other Income 6.91 16.74 -58.72% 6.50 2.10 209.52% 14.19 3.60 294.17% 9.50 2.89 228.72%
Interest 24.23 18.81 28.81% 23.52 13.18 78.45% 24.52 10.94 124.13% 22.26 15.17 46.74%
Depreciation 76.07 70.51 7.89% 73.77 69.04 6.85% 68.99 69.48 -0.71% 70.04 69.45 0.85%
PBT 222.30 179.56 23.80% 190.55 156.71 21.59% 192.61 183.23 5.12% 177.43 184.63 -3.90%
Tax 40.01 27.28 46.66% 36.47 22.49 62.16% 35.32 4.63 662.85% 40.09 4.13 870.70%
PAT 182.29 152.28 19.71% 154.08 134.22 14.80% 157.29 178.60 -11.93% 137.34 180.50 -23.91%
PATM 9.54% 9.24% 9.01% 8.59% 8.89% 11.77% 8.11% 11.07%
EPS 9.40 7.80 20.51% 7.85 6.85 14.60% 7.98 9.07 -12.02% 7.04 9.18 -23.31%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 6,267.14 6,032.63 5,874.06 5,149.00 5,035.40 5,066.88 4,132.56 3,660.28 2,945.26 2,985.90 3,009.02 Net Sales Growth 2.42% 2.70% 14.08% 2.26% -0.62% 22.61% 12.90% 24.28% -1.36% -0.77% Cost Of Goods Sold 1,929.29 1,788.77 1,800.35 1,660.13 1,502.21 1,304.03 1,045.87 1,000.08 893.36 915.74 854.53 Gross Profit 4,337.85 4,243.86 4,073.71 3,488.87 3,533.19 3,762.85 3,086.69 2,660.20 2,051.90 2,070.16 2,154.49 GP Margin 69.22% 70.35% 69.35% 67.76% 70.17% 74.26% 74.69% 72.68% 69.67% 69.33% 71.60% Total Expenditure 5,399.60 5,136.55 4,876.27 4,484.97 4,126.63 3,617.71 2,940.87 2,800.98 2,346.65 2,353.36 2,061.47 Power & Fuel Cost - 179.67 173.32 151.19 120.50 118.31 97.43 88.44 70.21 64.13 58.84 % Of Sales - 2.98% 2.95% 2.94% 2.39% 2.33% 2.36% 2.42% 2.38% 2.15% 1.96% Employee Cost - 1,466.57 1,335.91 1,094.82 1,062.30 976.13 806.37 684.45 582.72 527.46 453.32 % Of Sales - 24.31% 22.74% 21.26% 21.10% 19.26% 19.51% 18.70% 19.79% 17.67% 15.07% Manufacturing Exp. - 397.72 348.85 386.28 374.69 369.82 323.09 254.55 226.57 241.01 184.80 % Of Sales - 6.59% 5.94% 7.50% 7.44% 7.30% 7.82% 6.95% 7.69% 8.07% 6.14% General & Admin Exp. - 535.52 497.23 464.08 390.16 377.29 311.21 319.33 269.55 283.40 219.09 % Of Sales - 8.88% 8.46% 9.01% 7.75% 7.45% 7.53% 8.72% 9.15% 9.49% 7.28% Selling & Distn. Exp. - 724.78 673.69 679.85 647.93 445.87 318.14 422.79 273.56 298.84 266.86 % Of Sales - 12.01% 11.47% 13.20% 12.87% 8.80% 7.70% 11.55% 9.29% 10.01% 8.87% Miscellaneous Exp. - 43.52 46.92 48.62 28.84 26.26 38.76 31.34 30.68 22.78 266.86 % Of Sales - 0.72% 0.80% 0.94% 0.57% 0.52% 0.94% 0.86% 1.04% 0.76% 0.80% EBITDA 867.54 896.08 997.79 664.03 908.77 1,449.17 1,191.69 859.30 598.61 632.54 947.55 EBITDA Margin 13.84% 14.85% 16.99% 12.90% 18.05% 28.60% 28.84% 23.48% 20.32% 21.18% 31.49% Other Income 47.95 53.19 32.05 3.85 51.17 84.08 145.96 25.79 40.59 3.28 42.00 Interest 90.95 76.47 54.47 49.00 17.02 12.98 25.19 14.87 2.22 3.21 3.68 Depreciation 287.30 277.08 271.14 272.95 284.92 182.53 135.67 105.59 101.76 82.90 71.86 PBT 537.24 595.72 704.23 345.93 658.00 1,337.74 1,176.79 764.63 535.22 549.71 914.01 Tax 93.21 105.47 37.75 -0.80 114.45 241.20 197.39 153.42 113.23 119.08 215.27 Tax Rate 17.35% 17.33% 5.36% -0.23% 17.39% 18.03% 16.92% 20.06% 21.16% 21.66% 23.55% PAT 444.03 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 698.74 PAT before Minority Interest 444.03 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 698.74 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 7.09% 8.34% 11.35% 6.73% 10.79% 21.64% 23.46% 16.70% 14.33% 14.42% 23.22% PAT Growth -42.86% -24.51% 92.22% -36.21% -50.43% 13.12% 58.60% 44.84% -2.01% -38.37% EPS 22.59 25.59 33.90 17.64 27.65 55.78 49.31 31.09 21.46 21.90 35.54

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 7,083.26 6,672.08 6,228.63 5,652.62 5,305.78 5,393.14 4,605.76 3,934.69 3,130.81 3,134.61 3,165.99 Net Sales Growth 11.42% 7.12% 10.19% 6.54% -1.62% 17.10% 17.06% 25.68% -0.12% -0.99% Cost Of Goods Sold 1,893.48 1,793.36 1,715.08 1,708.82 1,446.43 1,257.35 1,039.38 992.71 886.19 887.57 823.95 Gross Profit 5,189.78 4,878.72 4,513.55 3,943.80 3,859.35 4,135.79 3,566.38 2,941.98 2,244.62 2,247.04 2,342.04 GP Margin 73.27% 73.12% 72.46% 69.77% 72.74% 76.69% 77.43% 74.77% 71.69% 71.68% 73.97% Total Expenditure 5,954.07 5,669.16 5,296.00 4,944.56 4,431.64 3,913.05 3,391.69 3,078.87 2,515.55 2,519.90 2,160.88 Power & Fuel Cost - 179.69 173.37 151.54 120.84 118.72 102.40 88.86 70.35 64.20 58.89 % Of Sales - 2.69% 2.78% 2.68% 2.28% 2.20% 2.22% 2.26% 2.25% 2.05% 1.86% Employee Cost - 1,562.34 1,446.29 1,169.13 1,133.00 1,051.17 906.44 746.69 622.81 558.83 472.85 % Of Sales - 23.42% 23.22% 20.68% 21.35% 19.49% 19.68% 18.98% 19.89% 17.83% 14.94% Manufacturing Exp. - 440.63 387.71 409.37 379.15 372.18 368.41 269.25 244.53 289.79 271.51 % Of Sales - 6.60% 6.22% 7.24% 7.15% 6.90% 8.00% 6.84% 7.81% 9.24% 8.58% General & Admin Exp. - 576.40 525.84 492.64 413.90 391.24 339.82 340.56 283.43 299.79 233.28 % Of Sales - 8.64% 8.44% 8.72% 7.80% 7.25% 7.38% 8.66% 9.05% 9.56% 7.37% Selling & Distn. Exp. - 1,064.86 996.88 952.30 890.38 687.41 531.19 590.28 380.21 393.14 274.14 % Of Sales - 15.96% 16.00% 16.85% 16.78% 12.75% 11.53% 15.00% 12.14% 12.54% 8.66% Miscellaneous Exp. - 51.88 50.83 60.76 47.94 34.98 104.05 50.52 28.03 26.58 274.14 % Of Sales - 0.78% 0.82% 1.07% 0.90% 0.65% 2.26% 1.28% 0.90% 0.85% 0.83% EBITDA 1,129.19 1,002.92 932.63 708.06 874.14 1,480.09 1,214.07 855.82 615.26 614.71 1,005.11 EBITDA Margin 15.94% 15.03% 14.97% 12.53% 16.48% 27.44% 26.36% 21.75% 19.65% 19.61% 31.75% Other Income 37.10 47.86 29.04 3.04 50.49 87.48 13.88 27.14 34.87 2.58 8.83 Interest 94.53 78.77 56.19 50.17 17.73 16.02 27.16 18.41 3.40 5.23 5.43 Depreciation 288.87 278.57 272.67 275.43 286.78 183.47 157.32 115.23 105.46 82.97 72.21 PBT 782.89 693.44 632.81 385.50 620.12 1,368.08 1,043.47 749.32 541.27 529.09 936.30 Tax 151.89 125.17 16.01 12.60 104.46 253.32 199.18 156.75 120.36 122.19 216.12 Tax Rate 19.40% 17.72% 2.53% 3.27% 16.85% 18.52% 19.92% 20.92% 22.24% 23.09% 23.08% PAT 631.00 583.42 615.82 341.99 520.94 1,114.76 828.76 593.65 420.72 406.99 720.18 PAT before Minority Interest 633.73 582.01 615.82 341.99 520.94 1,114.76 800.64 592.57 420.91 406.90 720.18 Minority Interest 2.73 1.41 0.00 0.00 0.00 0.00 28.12 1.08 -0.19 0.09 0.00 PAT Margin 8.91% 8.74% 9.89% 6.05% 9.82% 20.67% 17.99% 15.09% 13.44% 12.98% 22.75% PAT Growth -2.26% -5.26% 80.07% -34.35% -53.27% 34.51% 39.60% 41.10% 3.37% -43.49% EPS 32.10 29.68 31.32 17.40 26.50 56.70 42.15 30.20 21.40 20.70 36.63

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 5,194.74 4,908.91 4,414.29 5,290.34 5,101.81 3,346.02 2,712.41 2,194.63 1,867.32 1,530.73 Share Capital 39.31 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 37.70 Total Reserves 5,155.43 4,869.60 4,374.98 5,251.03 5,062.50 3,308.32 2,674.71 2,156.93 1,829.62 1,493.03 Non-Current Liabilities 84.51 83.59 86.67 204.25 403.08 1,079.25 595.88 585.07 101.00 83.91 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 0.00 Long Term Provisions 124.31 109.51 106.20 95.82 85.52 73.21 51.32 40.43 57.22 28.23 Current Liabilities 2,285.86 1,368.40 1,551.30 1,694.45 1,378.36 1,453.49 1,397.76 1,011.69 658.79 763.15 Trade Payables 724.57 619.96 595.86 570.21 527.00 393.17 472.75 601.98 430.11 499.76 Other Current Liabilities 230.05 222.34 250.41 515.60 557.86 222.12 375.65 140.28 80.35 51.32 Short Term Borrowings 1,142.22 420.04 635.07 430.00 0.02 800.04 359.98 121.53 8.28 0.00 Short Term Provisions 189.02 106.06 69.96 178.64 293.48 38.16 189.38 147.90 140.05 212.07 Total Liabilities 7,565.11 6,360.90 6,052.26 7,189.04 6,883.25 5,878.76 4,706.05 3,791.39 2,627.11 2,377.79 Net Block 2,513.47 2,535.66 2,377.47 1,771.10 1,773.82 1,276.46 1,085.44 918.30 799.01 697.25 Gross Block 4,100.64 3,859.15 3,441.30 2,733.11 2,452.31 1,761.68 1,435.06 1,162.61 948.64 1,082.45 Accumulated Depreciation 1,587.17 1,323.49 1,063.83 962.01 678.49 485.22 349.62 244.31 149.63 385.20 Non Current Assets 3,712.65 3,331.16 3,272.05 4,329.58 4,148.87 3,727.40 2,713.03 2,002.20 1,286.33 857.01 Capital Work in Progress 837.23 524.36 601.28 2,304.24 2,182.53 1,569.98 1,106.89 740.64 347.75 92.34 Non Current Investment 259.56 226.68 229.27 219.36 156.12 833.25 506.39 298.89 103.04 37.46 Long Term Loans & Adv. 102.39 44.46 64.03 34.88 36.40 47.71 14.31 44.37 36.53 29.96 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 3,852.46 3,029.74 2,780.21 2,859.46 2,734.38 2,151.36 1,993.02 1,789.19 1,340.78 1,520.78 Current Investments 0.00 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 0.00 Inventories 1,976.34 1,353.07 1,275.13 1,396.83 1,341.95 1,073.18 891.42 669.93 574.62 533.72 Sundry Debtors 1,480.67 1,340.12 1,201.20 988.33 421.86 784.11 539.78 621.66 467.41 371.50 Cash & Bank 20.84 26.49 28.46 21.90 61.44 37.13 150.80 15.63 7.21 284.81 Other Current Assets 374.61 53.26 48.19 44.71 722.16 256.94 411.02 481.97 291.54 330.75 Short Term Loans & Adv. 312.91 256.80 227.23 407.69 650.61 234.58 397.95 458.60 285.95 324.85 Net Current Assets 1,566.60 1,661.34 1,228.91 1,165.01 1,356.02 697.87 595.26 777.50 681.99 757.63 Total Assets 7,565.11 6,360.90 6,052.26 7,189.04 6,883.25 5,878.76 4,706.05 3,791.39 2,627.11 2,377.79

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 5,190.94 4,818.20 4,370.47 5,237.54 5,066.98 3,219.42 2,718.83 2,220.14 1,902.33 1,597.36 Share Capital 39.31 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 37.70 Total Reserves 5,151.63 4,778.89 4,331.16 5,198.23 5,027.67 3,181.72 2,681.13 2,182.44 1,864.63 1,559.66 Non-Current Liabilities 5.05 2.75 52.42 162.07 361.16 1,046.98 570.06 576.20 94.15 84.02 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 0.00 Long Term Provisions 124.31 109.51 106.20 95.82 85.52 74.51 52.03 40.76 57.22 28.23 Current Liabilities 2,514.27 1,520.28 1,640.80 1,830.59 1,533.26 1,751.61 1,663.65 1,267.18 813.96 944.19 Trade Payables 879.89 735.64 679.81 706.39 668.78 625.93 644.34 759.32 500.73 565.65 Other Current Liabilities 232.10 223.66 251.19 516.51 557.92 226.98 380.19 142.89 81.28 51.80 Short Term Borrowings 1,195.57 430.45 635.87 430.00 0.02 860.50 429.13 207.78 88.51 113.71 Short Term Provisions 206.71 130.53 73.93 177.69 306.54 38.20 209.99 157.19 143.44 213.03 Total Liabilities 7,708.84 6,341.23 6,063.69 7,230.20 6,961.40 5,989.05 4,951.75 4,063.83 2,810.55 2,625.57 Net Block 2,523.53 2,546.71 2,398.45 1,797.85 1,788.42 1,551.84 1,158.45 993.38 799.40 708.09 Gross Block 4,117.32 3,875.21 3,467.50 2,840.33 2,545.39 2,132.41 1,522.57 1,242.47 950.09 1,093.63 Accumulated Depreciation 1,593.79 1,328.50 1,069.05 1,042.48 756.97 580.57 364.12 249.09 150.69 385.54 Non Current Assets 3,519.12 3,197.39 3,149.80 4,255.37 4,056.96 3,526.30 2,820.02 2,116.31 1,316.80 917.30 Capital Work in Progress 837.23 524.36 601.28 2,304.24 2,182.53 1,846.18 1,551.23 1,010.15 396.28 92.52 Non Current Investment 127.21 93.02 96.33 118.40 49.31 17.62 48.76 41.64 49.88 53.43 Long Term Loans & Adv. 31.15 33.30 53.74 34.88 36.70 110.66 61.58 71.14 71.24 29.96 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.30 Current Assets 4,189.72 3,143.84 2,913.89 2,974.83 2,904.44 2,462.75 2,131.73 1,947.52 1,493.75 1,708.27 Current Investments 0.00 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 0.00 Inventories 2,288.14 1,643.54 1,475.27 1,609.70 1,486.15 1,187.54 967.27 733.93 632.75 569.79 Sundry Debtors 1,399.79 1,024.84 1,046.41 807.13 348.60 864.75 488.92 526.34 338.82 350.48 Cash & Bank 90.09 126.57 82.27 69.43 105.84 80.75 205.62 89.92 159.60 450.83 Other Current Assets 411.70 59.86 55.32 51.65 776.88 329.71 469.92 597.33 362.58 337.17 Short Term Loans & Adv. 342.52 289.03 254.62 436.92 698.21 301.61 451.71 569.84 355.02 330.08 Net Current Assets 1,675.45 1,623.56 1,273.09 1,144.24 1,371.18 711.14 468.08 680.34 679.79 764.08 Total Assets 7,708.84 6,341.23 6,063.69 7,230.20 6,961.40 5,989.05 4,951.75 4,063.83 2,810.55 2,625.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 226.57 772.77 730.25 545.26 1,388.48 539.75 808.80 304.55 327.16 847.52 PBT 608.59 704.23 345.93 658.01 1,337.74 1,166.79 764.63 535.22 549.71 914.01 Adjustment 365.07 284.21 448.49 413.35 92.60 30.14 91.48 81.90 84.88 72.96 Changes in Working Capital -701.42 -205.64 -10.39 -397.30 198.56 -460.39 110.38 -188.46 -189.44 56.63 Cash after chg. in Working capital 272.24 782.80 784.03 674.06 1,628.90 736.54 966.49 428.66 445.15 1,043.60 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -45.67 -10.03 -53.78 -128.80 -240.42 -196.79 -157.69 -124.11 -117.99 -196.08 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -636.08 -329.02 -460.98 -368.72 -835.72 -822.32 -753.60 -793.58 -510.97 -291.91 Net Fixed Assets -554.36 -340.93 994.77 -402.51 -1,303.18 -789.71 -638.70 -606.86 -121.60 -288.80 Net Investments -32.88 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 -4.13 Others -48.84 9.32 -1,445.84 -89.94 -22.70 294.25 92.60 9.13 -323.79 1.02 Cash from Financing Activity 403.61 -445.29 -261.16 -216.64 -533.75 166.13 79.67 497.80 -96.06 -276.05 Net Cash Inflow / Outflow -5.90 -1.54 8.11 -40.10 19.01 -116.44 134.87 8.77 -279.87 279.56 Opening Cash & Equivalents 20.13 21.67 13.56 53.66 35.58 144.25 9.45 0.68 280.56 0.99 Closing Cash & Equivalent 14.23 20.13 21.67 13.56 53.66 28.22 144.25 9.45 0.69 280.55

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 87.96 803.20 723.94 552.35 1,463.38 449.15 811.97 312.42 328.55 947.65 PBT 707.18 631.83 354.59 625.39 1,368.08 999.82 749.32 541.27 529.09 936.31 Adjustment 373.53 286.87 487.61 417.75 102.42 278.28 117.57 87.12 83.06 69.45 Changes in Working Capital -921.36 -95.65 -57.56 -367.36 238.30 -592.84 111.56 -180.85 -165.64 138.90 Cash after chg. in Working capital 159.35 823.05 784.64 675.78 1,708.80 685.26 978.45 447.54 446.51 1,144.66 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -71.39 -19.85 -60.70 -123.43 -245.42 -236.11 -166.48 -135.12 -117.96 -197.01 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -568.41 -320.61 -447.59 -371.97 -838.80 -731.63 -755.60 -884.38 -485.91 -306.80 Net Fixed Assets -554.36 -340.93 994.77 -402.51 -1,303.18 -789.71 -638.70 -606.86 -121.60 -288.80 Net Investments -32.88 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 -4.13 Others 18.83 17.73 -1,432.45 -93.19 -25.78 384.94 90.60 -81.67 -298.73 -13.87 Cash from Financing Activity 443.72 -437.86 -261.96 -217.35 -597.42 154.85 59.03 502.63 -128.88 -224.30 Net Cash Inflow / Outflow -36.73 44.73 14.39 -36.97 27.16 -127.63 115.40 -69.33 -286.24 416.55 Opening Cash & Equivalents 120.21 75.48 61.09 98.06 71.83 199.06 83.74 153.07 439.32 22.77 Closing Cash & Equivalent 83.48 120.21 75.48 61.09 98.06 71.84 199.07 83.74 153.08 439.32

Financial Ratios

Consolidated /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 264.30 249.75 224.59 269.16 259.57 177.51 143.89 116.43 99.06 81.21 ROA 7.23% 10.74% 5.24% 7.73% 17.18% 18.32% 14.39% 13.15% 17.21% 35.93% ROE 9.96% 14.30% 7.15% 10.46% 25.96% 32.00% 24.91% 20.78% 25.35% 59.11% ROCE 11.74% 14.62% 7.20% 11.72% 25.40% 27.08% 23.66% 22.91% 32.46% 71.75% Fixed Asset Turnover 1.52 1.61 1.67 1.94 2.41 2.59 2.82 2.79 2.94 3.19 Receivable days 85.33 78.96 77.61 51.11 43.44 58.46 57.91 67.48 51.27 43.03 Inventory Days 100.72 81.66 94.70 99.26 86.99 86.76 77.85 77.12 67.74 55.57 Payable days 137.18 123.25 128.19 133.30 128.78 54.44 74.24 86.97 79.07 76.51 Cash Conversion Cycle 48.88 37.36 44.12 17.08 1.65 90.78 61.52 57.63 39.94 22.09 Total Debt/Equity 0.22 0.09 0.14 0.12 0.10 0.50 0.39 0.28 0.00 0.00 Interest Cover 8.96 13.93 8.06 39.66 104.06 47.32 52.42 242.09 172.25 249.37

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 264.10 245.14 222.36 266.47 257.80 170.79 144.24 117.78 100.92 84.74 ROA 8.28% 9.93% 5.15% 7.34% 17.22% 14.64% 13.15% 12.25% 14.97% 33.76% ROE 11.63% 13.40% 7.12% 10.11% 26.91% 26.97% 24.00% 20.42% 23.25% 58.03% ROCE 13.51% 13.42% 7.44% 11.25% 26.28% 23.30% 22.66% 22.15% 28.87% 65.87% Fixed Asset Turnover 1.67 1.70 1.79 1.97 2.31 2.52 2.85 2.86 3.07 3.24 Receivable days 66.32 60.69 59.84 39.75 41.06 53.64 47.09 50.43 40.13 41.02 Inventory Days 107.54 91.38 99.60 106.49 90.48 85.38 78.91 79.67 70.01 54.91 Payable days 164.40 150.62 148.04 173.51 187.92 69.87 88.23 98.47 84.03 80.04 Cash Conversion Cycle 9.46 1.45 11.40 -27.27 -56.39 69.15 37.76 31.63 26.12 15.89 Total Debt/Equity 0.23 0.09 0.15 0.12 0.10 0.54 0.42 0.32 0.05 0.07 Interest Cover 9.98 12.24 8.07 36.27 86.40 37.81 41.70 160.20 102.16 173.43

Top Investors:

dsp midcap fund

life insurance corporation of india

kotak small cap fund

tata aia life insurance co ltd unit linked multi cap fund

investor education and protection fund (iepf)

llp

Annual Reports:

News Update:

Alembic Pharmaceuticals gets USFDA’s final nod for Sumatriptan Injection USP
7th Nov 2025, 18:20 PM

Alembic has a cumulative total of 228 ANDA approvals (207 final approvals and 21 tentative approvals) from USFDA
Read More
Alembic Pharma - Quarterly Results
5th Nov 2025, 00:00 AM

Read More
Alembic Pharma gets USFDA’s nod for Triamcinolone Acetonide Injectable Suspension
20th Oct 2025, 09:07 AM

The company has a cumulative total of 227 ANDA approvals (206 final approvals and 21 tentative approvals) from USFDA
Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Paroxetine Extended-Release Tablets
25th Sep 2025, 15:21 PM

The approved ANDA is therapeutically equivalent to the reference listed drug product, Paxil CR Extended-Release Tablets, 25 mg and 37.5 mg, of Apotex Inc
Read More
Alembic Pharmaceuticals gets EIR from USFDA for API - I, API - II facility at Panelav
15th Sep 2025, 11:00 AM

The inspection was conducted from May 26, 2025 to May 31, 2025
Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Phytonadione Injectable Emulsion USP
9th Sep 2025, 12:00 PM

Phytonadione Injectable Emulsion is indicated for the treatment of hypoprothrombinemia due to vitamin K deficiency or interference
Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Macitentan Tablets
19th Aug 2025, 12:30 PM

Macitentan Tablets, 10 mg, have an estimated market size of $1,180 million for twelve months ending June 2025 according to IQVIA
Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Tretinoin Cream
16th Aug 2025, 10:09 AM

The company has a cumulative total of 224 ANDA approvals (202 final approvals and 22 tentative approvals)
Read More
Alembic Pharmaceuticals reports 15% rise in Q1 consolidated net profit
5th Aug 2025, 16:29 PM

The consolidated total income of the company increased by 9.81% at Rs 1717.22 crore for Q1FY26
Read More

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: